After announcing that its phase 3 ATHOS-3 study would be published in a prestigious medical journal, clinical-stage biotech La Jolla Pharmaceutical (NASDAQ: LJPC) saw its shares jump by 24% as of 4 p.m. EDT on Thursday.
After announcing that its phase 3 ATHOS-3 study would be published in a prestigious medical journal, clinical-stage biotech La Jolla Pharmaceutical (NASDAQ: LJPC) saw its shares jump by 24% as of 4 p.m. EDT on Thursday.